Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Micronuclei and Nuclear Abnormalities in Oral Mucosa as Indicators of Genotoxicity in Healthcare Professionals.

Toxics·2026
Same author

Enhancing Cytosolic Internalization of [<sup>177</sup>Lu]Lu-iPSMA in Prostate Cancer Cells: The Effect of Conjugating a GRP78 Inhibitor to the Radiotherapeutic Molecule.

International journal of molecular sciences·2025
Same author

Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.

Pharmaceutics·2025
Same author

Assessment of the impact of the nuclear properties of<i>β</i><sup>-</sup>-emitting radionuclides on the dosimetry of two radiopharmaceuticals with distinct pharmacokinetics.

Physics in medicine and biology·2025
Same author

Charge Transfer Reactions (PDT Reaction I) Induced at 1064 nm (NIR-II) between Rhodamines and Folic Acid as the Basis for Biphotonic Photodynamic Therapy.

Journal of fluorescence·2025
Same author

Synthesis and Evaluation of [<sup>18</sup>F]AlF-NOTA-iPD-L1 as a Potential Theranostic Pair for [<sup>177</sup>Lu]Lu-DOTA-iPD-L1.

Pharmaceutics·2025

Related Experiment Video

Updated: Aug 23, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.8K

Engineered rHDL Nanoparticles as a Suitable Platform for Theranostic Applications.

Liliana Aranda-Lara1, Keila Isaac-Olivé1, Blanca Ocampo-García2

  • 1Faculty of Medicine, Universidad Autónoma del Estado de México, Toluca 50180, Estado de México, Mexico.

Molecules (Basel, Switzerland)
|October 27, 2022
PubMed
Summary

Researchers developed novel cholesterol-linked nanoparticles for cancer theranostics. These modified high-density lipoproteins (rHDLs) enable targeted drug delivery and imaging, enhancing cancer treatment potential.

Keywords:
apolipoprotein A1drug delivery systemshigh-density lipoproteinslutetium-nanoparticlesradiolabeled nanoparticlestechnetium-nanoparticlestheranostics

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

432
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

10.4K

Related Experiment Videos

Last Updated: Aug 23, 2025

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

2.8K
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

432
Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring
17:16

Registered Bioimaging of Nanomaterials for Diagnostic and Therapeutic Monitoring

Published on: December 9, 2010

10.4K

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Radiochemistry

Background:

  • Reconstituted high-density lipoproteins (rHDLs) are versatile platforms for drug and imaging agent delivery.
  • Scavenger Receptor Type B1 (SR-B1) on tumor cells facilitates specific rHDL uptake.
  • Cholesterol modification offers a novel site for functionalizing rHDL nanoparticles.

Purpose of the Study:

  • To synthesize cholesterol-conjugated bifunctional agents for rHDL surface modification.
  • To create HYNIC-rHDL and DOTA-rHDL nanoparticles for theranostic applications.
  • To evaluate the SR-B1 mediated cellular uptake and in vivo behavior of modified rHDLs.

Main Methods:

  • Synthesis of HYNIC-Cholesterol and DOTA-Cholesterol derivatives.
  • Preparation of HYNIC-rHDL and DOTA-rHDL nanoparticles.
  • In vitro assessment of SR-B1 recognition, internalization, and drug release in cancer cells.
  • In vivo biodistribution studies in mice.

Main Results:

  • HYNIC-rHDL and DOTA-rHDL nanoparticles were successfully synthesized and characterized.
  • Modified rHDLs retained SR-B1 specific recognition and cellular internalization.
  • HYNIC-rHDL showed similar biodistribution to unmodified rHDL, while DOTA-rHDL exhibited altered distribution.
  • Both systems demonstrated potential for targeted cancer theranostics.

Conclusions:

  • Cholesterol modification of rHDLs is a viable strategy for creating theranostic platforms.
  • These modified rHDLs can be radiolabeled for imaging and radiotherapy.
  • The developed nanoparticles show promise for personalized cancer treatment.